View Older Stories
-
Stifel Reiterates Buy Rating on Rhythm Pharmaceuticals (RYTM)
-
Rhythm Pharmaceuticals (RYTM) Tops Q4 EPS by 9c
-
RBC Capital Starts Rhythm Pharmaceuticals (RYTM) at Outperform; 'Set' Up to Hit High Notes in Rare Obesity'
-
Rhythm Pharmaceuticals (RYTM) PT Raised to $125 at H.C. Wainwright
-
Rhythm Pharmaceuticals (RYTM) PT Raised to $130 at TD Cowen
-
Rhythm Pharmaceuticals reports $57M Q4 revenue, 50% annual growth
-
Rhythm Pharmaceuticals (RYTM) PT Raised to $123 at H.C. Wainwright
-
Rhythm Pharmaceuticals (RYTM) PT Raised to $140 at Guggenheim
-
Rhythm Pharmaceuticals (RYTM) PT Raised to $141 at Canaccord Genuity
-
Rhythm Pharmaceuticals (RYTM) PT Raised to $167 at Citizens
-
Rhythm Pharmaceuticals (RYTM) PT Raised to $157 at Goldman Sachs
-
TD Cowen Reiterates Buy Rating on Rhythm Pharmaceuticals (RYTM)
-
Rhythm Pharmaceuticals (RYTM) PT Raised to $150 at Morgan Stanley
-
Raymond James on Aardvark (AARD): 'we think ARD-101’s value proposition as potentially best-in-class
-
Rhythm Pharmaceuticals (RYTM) PT Raised to $145 at Needham
-
Citi Starts Rhythm Pharmaceuticals (RYTM) at Buy, PT $136
-
Rhythm Pharmaceuticals (RYTM) PT Lowered to $141 at Goldman Sachs
-
Rhythm Pharmaceuticals faces FDA review delay for obesity drug
-
Rhythm gets public reimbursement for IMCIVREE in five Canadian provinces
-
Oppenheimer Downgrades Rhythm Pharmaceuticals (RYTM) to Perform
-
Rhythm Pharmaceuticals (RYTM) Misses Q3 EPS by 11c, provides guidance
-
Rhythm Pharmaceuticals (RYTM) PT Raised to $110 at H.C. Wainwright
-
Stifel Reiterates Buy Rating on Rhythm Pharmaceuticals (RYTM)
-
Citizens JMP Reiterates Market Outperform Rating on Rhythm Pharmaceuticals (RYTM)
-
Rhythm Pharmaceuticals (RYTM) PT Raised to $157 at Goldman Sachs
-
Rhythm Pharmaceuticals (RYTM) PT Raised to $122 at Morgan Stanley
-
Citizens JMP Reiterates Market Outperform Rating on Rapport Therapeutics (RAPP)
-
Citizens JMP Reiterates Market Outperform Rating on Abivax (ABVX)
-
Citizens JMP Reiterates Market Outperform Rating on Rhythm Pharmaceuticals (RYTM)
-
FDA accepts Rhythm Pharmaceuticals' setmelanotide filing for rare obesity
-
Rhythm Pharmaceuticals (RYTM) PT Raised to $100 at H.C. Wainwright
-
Rhythm Pharmaceuticals (RYTM) PT Raised to $135 at Citizens JMP
-
Rhythm Pharmaceuticals (RYTM) PT Raised to $110 at TD Cowen
-
Rhythm Pharmaceuticals (RYTM) Misses Q2 EPS by 8c
-
Rhythm Pharmaceuticals (RYTM) PT Raised to $105 at Canaccord Genuity
-
Rhythm Pharmaceuticals (RYTM) PT Raised to $109 at BofA Securities
-
Citizens JMP Upgrades Rhythm Pharmaceuticals (RYTM) to Market Outperform
-
Morgan Stanley Reiterates Overweight Rating on Rhythm Pharmaceuticals (RYTM)
-
Goldman Sachs Resumes Rhythm Pharmaceuticals (RYTM) at Buy
-
Rhythm Pharmaceuticals prices $175 million stock offering at $85 per share
-
Rhythm Pharmaceuticals (RYTM) PT Raised to $110 at Oppenheimer
-
Rhythm Pharmaceuticals (RYTM) PT Raised to $102 at Leerink Partners
-
Rhythm Pharmaceuticals announces $150 million stock offering
-
Rhythm Pharmaceuticals (RYTM) PT Raised to $123 at Stifel
-
Rhythm Pharmaceuticals (RYTM) PT Raised to $95 at BofA Securities
-
Stifel on Rhythm Pharmaceuticals (RYTM): 'Bivamelagon Data Look Very Solid and Meet/Exceed Our Bar'
-
Rhythm Pharmaceuticals' bivamelagon shows BMI reduction in obesity trial
-
Rhythm Pharmaceuticals to report phase 2 trial results for obesity drug
-
Leerink Partners Starts Rhythm Pharmaceuticals (RYTM) at Outperform
-
Citizens JMP Reiterates Market Outperform Rating on Rhythm Pharmaceuticals (RYTM)

